Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...

Health Canada has approved Pfizer-BioNTech’s updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus. The mRNA vaccine, called Comirnaty ...

Pfizer-BioNTech's mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version that targeted the XBB.1.5 Omicron subvariant.

EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...